Nanoemulsion containing kojic dipalmitate and rosehip oil : a promising formulation to treat melasma
dc.contributor.author | Zilles, Júlia Capp | pt_BR |
dc.contributor.author | Duarte, Larissa Pedron | pt_BR |
dc.contributor.author | Ruaro, Thais Carine | pt_BR |
dc.contributor.author | Zimmer, Aline Rigon | pt_BR |
dc.contributor.author | Külkamp-Guerreiro, Irene Clemes | pt_BR |
dc.contributor.author | Contri, Renata Vidor | pt_BR |
dc.date.accessioned | 2023-06-17T03:37:50Z | pt_BR |
dc.date.issued | 2023 | pt_BR |
dc.identifier.issn | 1999-4923 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/259127 | pt_BR |
dc.description.abstract | Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy method (Ultra-Turrax®) was used to develop nanoemulsions containing up to 2 mg/mL KDP, 5% rosehip oil, and 7.5% surfactant. Formulations were characterized regarding droplet size, size distribution, pH, density, morphology, KDP content, incorporation efficiency, and stability under different temperature conditions. A scale-up study was conducted. Skin permeation, antioxidant potential, and tyrosinase inhibitory activity were assessed in vitro. Cell viability studies were also performed. Results showed that nanoemulsions containing 1 and 2 mg/mL KDP had incorporation efficiencies greater than 95%, droplet size smaller than 130 nm, suitable size distribution, zeta potential of approximately 10 mV, and good stability over 30 days of refrigerated storage. The nanoemulsion containing 1 mg/mL KDP was chosen for further evaluation because it had lower nanocrystal formation, greater scale-up feasibility and allowed KDP permeation up to the epidermis similarly than observed for 2 mg/mL KDP. This formulation (1 mg/mL KDP) showed antioxidant and depigmenting efficacy, close to that of 1 mM ascorbic acid. No cytotoxicity was observed in formulations concentrations ranging from 0.06% to 1%. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Pharmaceutics. Basel. Vol. 15, n. 2 (2023), 468, 16 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Antioxidant | en |
dc.subject | Antioxidantes | pt_BR |
dc.subject | Melanose : Tratamento farmacológico | pt_BR |
dc.subject | Kojic dipalmitate | en |
dc.subject | Nanoemulsion | en |
dc.subject | Rosehip oil | en |
dc.subject | Tyrosinase inhibition | en |
dc.title | Nanoemulsion containing kojic dipalmitate and rosehip oil : a promising formulation to treat melasma | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001163293 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (39166)Ciências da Saúde (10550)